N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma

Abstract

BackgroundPapillary renal cell carcinoma (RCC) represents a rare tumor, which is divided, based on histological criteria, into two subtypes. In contrast to type I papillary RCC type II papillary RCC shows a worse prognosis. So far, reliable immunohistochemical markers for the distinction of these subtypes are not available.MethodsIn the present study the expression of N(neural)-, E(epithelial)-, P(placental)-, und KSP(kidney specific)-cadherin was examined in 22 papillary RCC of histological type I and 18 papillary RCC of histological type II (n = 40).ResultsAll papillary RCC type II displayed a membranous expression for N-cadherin, whereas type I did not show any membranous positivity for N-cadherin. E-cadherin exhibited a stronger, but not significant, membranous as well as cytoplasmic expression in type II than in type I papillary RCC. A diagnostic relevant expression of P- and KSP-cadherin could not be demonstrated in both tumor entities.ConclusionThus N-cadherin represents the first immunhistochemical marker for a clear cut differentiation between papillary RCC type I and type II and could be a target for therapy and diagnostic in the future.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2011556982761733

Acquired cystic disease‐associated renal cell carcinoma with a focal sarcomatoid component: Report of a case showing more pronounced polysomy of chromosomes 3 and 16 in the sarcomatoid component

“…In one study of papillary RCCs, membranous positivity for N‐cadherin was shown in all papillary RCCs of histological type II, while type I did not display any membranous expression for N‐cadherin. E‐cadherin, which is expressed in both types, exhibited a stronger immunopositivity in type II than in type I . The N‐ and E‐cadherin expression patterns in our case were different from these papillary RCCs.…”

RETRACTED ARTICLE: Collecting duct carcinoma of the kidney: a clinicopathological study of five cases

“…Genetical analyses include gene copy numbers, chromosomal imbalances, gene mutations and single nucleotide polymorphism (SNP) analysis [18]. Many biomolecules, including epithelial-mesenchymal transition (EMT) markers such as N-cadherin [22] and vimentin [19] and human leucocyte molecules such as HLA-G and HLA-E [23], are reported to be biomarkers for renal cancer. Immunohistochemical examination of these biomarkers is important for the determination of the origin and the diagnosis of CDC.…”

Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients

“…However, the switch in expression from E-cadherin to N-cadherin and the higher expression of N-cadherin in patients with a poor prognosis were demonstrated in this study. Recent study also showed that N-cadherin was highly expressed in type II papillary renal cell carcinomas than type I cancers and type II cancers were related to poor prognosis [29]. …”